# AIMIRA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aimira

- Industry: Medical Devices & Equipment
- Headquarters: Guangzhou, China
- Website: www.aimirainnovation.com
- Latest round: Angel (May 31, 2022)
- Investors on record: 1

## About

Established in 2021, and based in Guangzhou, China, Guangzhou Mira Innovation Technology Co., Ltd., trading as AIMIRA,, is a medical equipment company that provides medical robots for anti-ageing medicine. The company's core founding team consists of scientists from University College London and other colleges in the UK. The company's project has been supported by landing policies in two cities in China. In September 2025, it closed a pre-series A+ funding round from Guangzhou Guoju Venture Capital, Guangzhou Industry Investment Holding Group, Wanlian Tianze, Huajin Dadao Investment, Jiangxia Science and Technology Investment Group, Suikai Equity Investment and XIAMEN SOLEX HIGH-TECH INDUSTRIES CO.,LTD.

The company develops AI-enabled medical robotics platforms and intelligent hardware that integrate imaging, multi-modal sensing, and energy delivery systems. Its products include robots designed for medical aesthetics and anti-aging procedures, incorporating deep learning algorithms, high-precision imaging, and adaptive energy control technologies. The company’s hardware platform combines modalities such as plasma, laser, radiofrequency, and ultrasound to provide non-invasive treatment solutions, complemented by intelligent injection systems and 3D imaging. These systems target clinical applications in skin and soft tissue treatment, medical aesthetics and functional rejuvenation.

The company generates revenue through the development and commercialization of AI medical robots and intelligent hardware systems, with income expected from clinical device sales, hospital partnerships, licensing of proprietary technologies and long-term service agreements for maintenance and compliance support.

AIMIRA plans to use its latest funding round to accelerate regulatory approvals and clinical trials, advance core technology iterations, and expand large-scale manufacturing capacity under GMP and international quality standards. The company also intends to strengthen its compliance framework and pursue domestic and international market expansion to scale adoption of its medical robotics solutions.

## Funding rounds

- Angel, May 31, 2022 — Yigao Capital

## Investors

- Yigao Capital (https://capitalatlas.ai/funds/yigao-capital) — Angel